ZPE-77 Research Program

What It Is

An Investigational Metabolic Research Platform
ZPE-77 is an investigational biotechnology research program focused on advanced metabolic regulation
science.
It is a laboratory-stage platform exploring precision biologic delivery systems, cellular energy regulation
models, and systems level metabolic signaling frameworks.
ZPE-77 is not an FDA approved therapy.
It is not commercially available.
It is not indicated for the diagnosis, treatment, cure, or prevention of any disease.
The program currently exists in research and preclinical development stages, with ongoing efforts
centered on mechanistic modeling, formulation design, and biological validation strategies.
The objective of ZPE-77 is scientific discovery not clinical deployment.

Why It’s Being Studied

Metabolic disease remains one of the most complex and progressive conditions in modern medicine.

Current pharmacologic approaches can meaningfully improve glycemic control and body weight
however, many require chronic administration and long term adherence.

ZPE-77 is being studied to explore foundational scientific questions:

• Can metabolic signaling be influenced at deeper regulatory layers?
• Are there opportunities to improve durability of metabolic adaptations?
• Can advanced biologic delivery systems enhance cellular level modulation?
• What mechanisms govern long term metabolic resilience?

These are research questions not clinical claims.
The ZPE-77 initiative is designed to investigate whether new biological frameworks can expand
understanding of metabolic regulation beyond current paradigms.

Current Scientific Context

Established GLP-1 Based Therapies

GLP-1 receptor agonists, including semaglutide, represent a major advancement in metabolic medicine.
These therapies have demonstrated:
• Reduction in HbA1c in type 2 diabetes
• Clinically meaningful weight reduction
• Cardiovascular risk reduction in certain populations
• Multi-year safety data under regulatory review
GLP-1 therapies function primarily through incretin hormone pathways that influence appetite regulation,
gastric emptying, and insulin secretion.
They are supported by large-scale clinical trials and are approved for specific indications.
Neo Quantum Era recognizes and respects the role of these therapies in modern metabolic management.
ZPE-77 is not positioned as a replacement for GLP-1 therapies.
Rather, it is a research initiative seeking to explore adjacent and deeper biological questions.

Long Term Research Vision

Established GLP-1 Based Therapies

Expanding the Boundaries of Metabolic Science
The ZPE-77 research platform is built on the hypothesis that metabolic disease involves complex cellular
signaling networks extending beyond single-pathway hormone modulation.

The long-term scientific vision includes exploring:
• Systems-level metabolic signaling architecture
• Cellular energy utilization dynamics
• Precision nano-biologic transport models
• Durability frameworks for long-term metabolic adaptation
All future development would require:
• Comprehensive preclinical validation
• Phase I–III human clinical trials
• Independent peer-reviewed publication
• Regulatory approval
Innovation in metabolic science must be grounded in evidence, reproducibility, and transparency.
ZPE-77 represents a commitment to expanding the scientific conversation responsibly.

Development Status

Research and Preclinical Phase

ZPE-77 is currently in research and preclinical development.
There are:
• No completed Phase I–III human clinical trials
• No established therapeutic indications
• No regulatory approvals
Any potential future clinical application would depend on:
• Demonstrated safety
• Demonstrated efficacy
• Regulatory review
• Independent scientific validation
ZPE-77 remains an investigational research platform.

Disclaimer

Neo Quantum Era is a research and development organization. Collaborations are conducted for scientific research purposes only. No investigational platforms or materials are approved for clinical or commercial use.